Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash & Equivalents: 2022-2024

Historic Cash & Equivalents for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $125.0 million.

  • Day One Biopharmaceuticals' Cash & Equivalents fell 89.76% to $43.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.3 million, marking a year-over-year decrease of 89.76%. This contributed to the annual value of $125.0 million for FY2024, which is 45.85% down from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Cash & Equivalents of $125.0 million as of FY2024, which was down 45.85% from $230.8 million recorded in FY2023.
  • Over the past 5 years, Day One Biopharmaceuticals' Cash & Equivalents peaked at $230.8 million during FY2023, and registered a low of $85.3 million during FY2022.
  • In the last 3 years, Day One Biopharmaceuticals' Cash & Equivalents had a median value of $125.0 million in 2024 and averaged $147.0 million.
  • In the last 5 years, Day One Biopharmaceuticals' Cash & Equivalents soared by 170.68% in 2023 and then crashed by 45.85% in 2024.
  • Day One Biopharmaceuticals' Cash & Equivalents (Yearly) stood at $85.3 million in 2022, then soared by 170.68% to $230.8 million in 2023, then plummeted by 45.85% to $125.0 million in 2024.